FibroBiologics Inc. (NASDAQ:FBLG – Free Report) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for FibroBiologics in a report issued on Thursday, April 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($1.31) per share for the quarter, up from their prior forecast of ($1.40). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($4.41) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.49) EPS, FY2028 earnings at ($5.53) EPS, FY2029 earnings at ($6.75) EPS and FY2030 earnings at ($6.05) EPS.
Other equities analysts have also recently issued research reports about the company. Wall Street Zen raised FibroBiologics to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a research note on Thursday, January 22nd. Finally, D. Boral Capital restated a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $74.00.
FibroBiologics Stock Performance
NASDAQ FBLG opened at $1.52 on Monday. FibroBiologics has a twelve month low of $1.03 and a twelve month high of $30.60. The stock has a market capitalization of $5.34 million, a PE ratio of -0.18 and a beta of 1.07. The stock has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $5.84.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.06.
Insider Buying and Selling
In other FibroBiologics news, CFO Jason Davis purchased 3,500 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were acquired at an average cost of $8.20 per share, for a total transaction of $28,700.00. Following the transaction, the chief financial officer directly owned 3,500 shares in the company, valued at approximately $28,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders purchased 9,574 shares of company stock worth $72,886. 13.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On FibroBiologics
A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in FibroBiologics during the 4th quarter worth $34,000. Renaissance Technologies LLC lifted its holdings in FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after buying an additional 171,800 shares in the last quarter. Geode Capital Management LLC lifted its holdings in FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after buying an additional 59,813 shares in the last quarter. AMG National Trust Bank acquired a new position in FibroBiologics during the 4th quarter worth $31,000. Finally, Yorkville Advisors Global LP acquired a new position in FibroBiologics during the 3rd quarter worth $278,000.
About FibroBiologics
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Further Reading
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
